Ligand Pharmaceuticals Incorporated
$231.78
▼
-0.02%
2026-04-21 07:53:00
www.ligand.com
NGM: LGND
Explore Ligand Pharmaceuticals Incorporated stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.59 B
Current Price
$231.78
52W High / Low
$238.31 / $98.89
Stock P/E
36.85
Book Value
$51.44
Dividend Yield
—
ROCE
3.1%
ROE
13.47%
Face Value
—
EPS
$6.13
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
47
Beta
1
Debt / Equity
44.39
Current Ratio
22.23
Quick Ratio
21.98
Forward P/E
20.7
Price / Sales
15.24
Enterprise Value
$3.8 B
EV / EBITDA
46.98
EV / Revenue
14.19
Rating
None
Target Price
$245.1
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Capital efficiency is modest.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Seres Therapeutics, Inc. | $8.94 | 15.05 | $85.7 M | — | -79.05% | 19.64% | $29.98 / $6.53 | $4.63 |
| 2. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
| 3. | OS Therapies Incorporated | $1.38 | — | $58.43 M | — | 582.87% | 614.26% | $2.57 / $1.15 | $-0.16 |
| 4. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
| 5. | Pulmatrix, Inc. | $1.34 | — | $4.91 M | — | -135.67% | -80.93% | $9.37 / $1.16 | $1.04 |
| 6. | Sensei Biotherapeutics, Inc. | $31.39 | — | $42.07 M | — | -119.5% | -74.01% | $36.76 / $5.25 | $18.24 |
| 7. | Ascentage Pharma Group Internat | $25.65 | — | $18.58 B | — | -25.48% | -1.55% | $95.35 / $36.5 | $0.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 59.67 M | 115.46 M | 47.63 M | 45.33 M | 42.81 M | — |
| Operating Profit | 20.04 M | 54.1 M | 9.72 M | -36.66 M | 1.69 M | — |
| Net Profit | 44.78 M | 117.27 M | 4.85 M | -42.45 M | -31.09 M | — |
| EPS in Rs | 2.25 | 5.88 | 0.24 | -2.13 | -1.56 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 268.09 M | 167.13 M | 131.31 M | 196.25 M |
| Operating Profit | 47.2 M | 23.02 M | 9.82 M | 3.04 M |
| Net Profit | 124.45 M | -4.03 M | 52.15 M | -33.36 M |
| EPS in Rs | 6.24 | -0.2 | 2.62 | -1.67 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.56 B | 941.77 M | 787.22 M | 762.67 M |
| Total Liabilities | 543.42 M | 111.33 M | 86.3 M | 165.18 M |
| Equity | 1.02 B | 830.44 M | 700.91 M | 597.49 M |
| Current Assets | 832.27 M | 331.56 M | 237.43 M | 263.6 M |
| Current Liabilities | 37.45 M | 37.11 M | 16.78 M | 98.81 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 49.36 M | 97.05 M | 49.58 M | 137.85 M |
| Investing CF | -377.32 M | -143.66 M | -11.68 M | 163.62 M |
| Financing CF | 428.22 M | 97.14 M | -59.95 M | -275.99 M |
| Free CF | 38.05 M | 77.41 M | -4.27 M | 119.93 M |
| Capex | -11.31 M | -19.64 M | -53.85 M | -17.92 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 27.28% | -33.09% | — | — |
| Earnings Growth % | -107.73% | 256.33% | — | — |
| Profit Margin % | -2.41% | 39.72% | -17% | — |
| Operating Margin % | 13.77% | 7.48% | 1.55% | — |
| Gross Margin % | 93.37% | 91.99% | 73.08% | — |
| EBITDA Margin % | 24.41% | 76.79% | 45.53% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-11-02 | 1:1.603 |